EXPLORING THE EVIDENCE: GLP-1 RAs in Individuals with T2D and ASCVD

Pre-registration for:
EXPLORING THE EVIDENCE: GLP-1 RAs in Individuals with T2D and ASCVD

SUNDAY, NOVEMBER 9, 2025

HILTON RIVERSIDE
Grand Salon C, 1st Floor
2 Poydras St.
New Orleans, Louisiana

Register using the form provided below. Click HERE for additional meeting details.
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) risk have significant challenges to control their blood glucose, reduce body mass index (BMI) and decrease their risk of myocardial infarction, stroke and cardiovascular death. The discovery and approval of injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) has markedly improved management and outcomes for these patients. The 2025 American Diabetes Association (ADA) Standards of Care in Diabetes recommend T2D patients with or at high risk for ASCVD, heart failure, or chronic kidney disease should be treated with a cardioprotective GLP-1 RA and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor as part of the comprehensive approach to cardiovascular and kidney risk reduction. However, not all patients will self-inject GLP-1RAs on a weekly basis. Having an orally available agent that has shown glycemic control and reduction in cardiovascular risk is a huge therapeutic advance; cardiovascular clinicians caring for these patients need to understand the evidence for the use of an oral GLP-1RA and how it fits into their therapeutic armamentarium for patient treatment. In this symposium, an expert faculty will discuss the data with injectable GLP-1 RAs in ASCVD patients and the place of injectable GLP-1 RAs in reduction of cardiovascular risk. The design, efficacy and safety results from the SOUL trial will be presented, as well as the latest meta-analyses with GLP-1 RAs. Cases of patients with T2D and ASCVD will be presented, and attendees will be provided with best practices incorporating evidence-based clinical decision-making and patient-centered care.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the key injectable GLP-1 RA clinical trials and metaanalyses in patients with T2D and high ASCVD risk.
  • Explain the American Diabetes Association 2025 guideline recommendations for the use of GLP-1 RAs in patients with T2D and ASCVD or multiple risk factors for ASCVD.
  • Interpret the evidence from the SOUL trial and describe the potential role for oral GLP-1 RA therapy in patients with T2D and high risk.

Target Audience:

This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Accreditation and Credit Designation Statements

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Grant:

Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 1 Bethany Rd. Bldg 3, Suite 48, Hazlet, NJ 07730. Phone: 973-467-0500.